anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method of recombinant yeast for the surface display of white spot syndrome virus (WSSV) protein VP37, comprising the steps of: constructing a fused expression recombinant plasmid by using a surface display carrier pYD1 of the yeast and the gene recombination of the WSSV protein VP37, and transforming the brewing yeast EBY100 to obtain the recombinant yeast for the surface display of the VP37. The preparation method is characterized in that the recombinant yeast EBY100 containing the WSSV protein VP37 gene has VP37 on the surface. The invention also provides the application of a recombinant yeast live vaccine for the surface display of the WSSV VP37 in the cultivation of crustaceans. The prepared recombinant yeast can be used as an oral vaccine for immunizing the shrimps and protecting the shrimps against the WSSV. The genetic engineering live vaccine in the invention has the advantages that the brewing yeast is safe, and the cultivation method is simple and easy, and convenient for mass production. Relative to other vaccines, the displayed VP37 protein is easy to be identified by an immune system and has good stability.
Nonalcoholic fatty liver disease (NAFLD) is fatty liver mainly related to metabolic syndrome. NAFLD with inflammation and hepatocellular damage is defined as nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. We have previously reported that a hexane insoluble fraction from an anthocyanin-rich purple rice ethanolic extract (PRE-HIF) can suppress prostate carcinogenesis. However, the extract's effect on NASH has not yet been established. In the present study, we investigated the chemopreventive effect of a PRE-HIF on NASH and liver fibrosis using a connexin 32 (Cx32) dominant negative transgenic (Cx32ΔTg) rat NASH model. Seven-week-old male Cx32ΔTg rats were fed a control diet, a high-fat diet (HFD), or an HFD with 1% PRE-HIF and intraperitoneal administration of dimethylnitrosamine for 17 weeks. Histological findings of NASH such as fat deposition, lobular inflammation, hepatocyte ballooning injury, and bridging fibrosis were observed in the HFD group but not in the control group, and all histological parameters were significantly improved by PRE-HIF treatment. Corresponding to the histological changes, increased expression of inflammatory cytokine mRNAs (TNF-α, IL-6, IL-18, IFN-γ, IL-1β, TGF-β1, TIMP1, TIMP2, COL1A1), along with and activation of nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) signaling were observed in the HFD group, which was significantly decreased by PRE-HIF. The number and area of hepatic precancerous glutathione S-transferase placental form-positive foci tended to be decreased by PRE-HIF. These results indicate that intake of purple rice as a dietary supplement may reduce steatohepatitis, liver injury, and fibrosis in NASH by inactivation of NF-κB or JNK.
A method for the removal from the skin of the active phenolic compounds which cause an allergic response in some individuals who have been exposed to oils of plants of the Anacardiacea family, of which poison ivy and poison oak are representative. The method utilizes hydrophilic anion exchange material applied topically to the affected skin area in a suitable carrier, such as in a buffered aqueous suspension. Following sufficient contact time (i.e. about 20 to 60 minutes) the anion exchange material is removed and discarded. The treated area is rinsed with water and dried. The method has been found to be effective in the rapid removal of the vesicant principles of poison ivy and poison oak. The materials are inexpensive and accepted as safe for topical use. They are stable and easily applied without medical assistance.
Patients enrolled at their pre-op appointments (visit 0 - egligibilty criterias are verified and the consent collected). Visit 1 (0 to 90 days after visit 0) is a surgery. TIM measurements, icluding deep sound and spectroscopy, are performed after the CI and all adverse events are noted. CBCT is routinely done the next day after CI. TIM measurements (as well as adverse event collection) are repeated during visits 2, 3, 4, 5 and 6 (appoitments 15 days, 1, 2, 3 and 6 months after the surgery).
The data reduction apparatus is used in a system where speech signals, e.g. between telephones, are digitised in a circuit and later reconverted. Successive blocks of digitised data, e.g. 16m seconds thereof, are compared with each other in the frequency domain in a comparator. The conversion is effected in a circuit block. If one block is similar to its predecessor within pre-set limits, that block is not sent to the output, and instead a control signal is passed to the communication link to instruct a store to repeat the previous block at the other end of the communication link. Thus only critical data blocks are transmitted and the data rate is reduced.
The percentage of patients in clinical studies for venlafaxine hydrochloride extended-release capsules for MDD, GAD, SAD, and PD who were 65 years of age or older are shown in Table 15.

No overall differences in effectiveness or safety were observed between geriatric patients and younger patients, and other reported clinical experience generally has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including venlafaxine hydrochloride extended-release capsules, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [ see Warnings and Precautions ( 5.9) ]. 

The pharmacokinetics of venlafaxine and ODV are not substantially altered in the elderly [ see Clinical Pharmacology ( 12.3)] (see Figure 3). No dose adjustment is recommended for the elderly on the basis of age alone, although other clinical circumstances, some of which may be more common in the elderly, such as renal or hepatic impairment, may warrant a dose reduction [ see Dosage and Administration ( 2.6) ].
Detailed surgical procedures and related instructions have been published in "Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer" J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11.
In this study, subjects were divided into two groups, one group was supplied with a test product containing an over-the-counter (OTC) drug monographed ingredient for treatment of eczema. The other group was supplied with a cosmetic test product which is a standard dry skin daily moisturizer. Both groups were also provided with a cosmetic test cleanser to use in place of their normal cleanser. Subjects used the products for 14 days, followed by a 7-day regression period (no product use).

Subjects were assessed at Baseline and at Day 1, Day 3, Day 7, and Day 14 of product use. They were assessed again 7 days after stopping product use. Only the group provided with the test product containing the monograph ingredient for treatment of eczema were assessed for eczema endpoints after the Baseline visit.
Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
A computer implemented method for generating a ballpark clinical trial budget based on User (Sponsors/Researchers) input of clinical trial project related specifications and a set of predefined assumptions from a predefined database. The generated budget is graphically displayed in the form of an interactive and completely editable multilevel doughnut chart. The User can then review and edit any of the predefined assumption used in the computation of the budget and save it as a new version of the trial project's budget. A summary of the budget can also be printed out. The User can review and shortlist the service providers to provide deliverables for the clinical trial and finance management interface enables interaction between the User and the service providers to further discuss. The method can be modified to generate budgets and business intelligence in any organization to aid various operations.
A communication system (12) of a service center (10) communicates information such as analytical data with a plurality of automatic analyzers (100). A database (16) stores such information. An evaluation system (14) uses analytic data in the database to evaluate and analyze the analytical results obtained by the automatic analyzers by using analytical information stored in this database. The reagent parameter registration system (18) registers information about the reagents in the database (16). In response to a request from any of the automatic analyzers, the communication system (12) accesses the database to retrieve the information about the analytical parameters of the reagents to be managed, and forwards it to the automatic analyzer. This method facilitates setting parameters of test items of an analysis that uses reagents.
OBJECTIVE: This study aimed to analyse the family resilience of patients with stress urinary incontinence (SUI) after cervical cancer surgery and its influencing factors.
METHODS: Patients with cervical cancer postoperative SUI admitted to our hospital from May 2020, to May 2023, were retrospectively selected. They were divided into low-resilience group and high-resilience group in accordance with the Family Resilience Questionnaire (FaREQ). The general demographic data of the two groups were statistically analysed, and correlation and logistic regression analyses were performed.
RESULTS: The FaREQ score of 222 patients was (93.61 ± 8.45). Amongst these patients, 21.62% scored less than 84 points, and 78.38% scored more than 84 points. Significant differences were found in the educational level, indwelling catheter time, family monthly income, religious belief, hope index, psychological resilience, family function and social support between the two groups (p < 0.05). A significant positive correlation was observed between family resilience and the above indicators (p < 0.05). The variance inflation coefficient values of educational level and indwelling catheter time were 15.764 and 43.766, and the tolerance values were 0.063 and 0.023, respectively. After removing them, family monthly income, religious belief, hope index, psychological resilience, family function and social support were the factors affecting the family resilience level of patients with SUI after cervical cancer surgery.
CONCLUSIONS: The level of family resilience of patients with SUI after cervical cancer surgery is low. Many factors, such as family monthly income and religious belief, affect the level of resilience. Therefore, corresponding measures could be formulated in advance to improve the level of family resilience of such patients.
Pancreatic fluid collection is a late complication of severe acute pancreatitis. According to the revised Atlanta classification, walled-off necrosis (WON) is defined as an encapsulated collection of necrotic tissue that is observed after four weeks of the onset of acute pancreatitis. Infected WON is associated with high morbidity and mortality; therefore, an appropriate treatment, including antibiotics and drainage, is mandatory. With the development of endoscopic equipment, endoscopic ultrasonography (EUS)-guided drainage has become a first-line treatment modality for infected WON. For patients who are refractory to EUS-guided drainage, endoscopic necrosectomy (EN) is a treatment option to facilitate direct removal of infected necrotic tissue within the WON. However, due to potentially lethal adverse events of EN, such as bleeding, perforation, and peritonitis, EN is usually withheld for several days after EUS-guided drainage. This strategy is known as "the step-up approach." Recently, with the accumulated evidence supporting the safety of EN, especially with the use of a dedicated lumen-apposing metal stent, it has been reported that EN immediately after EUS-guided drainage can shorten the treatment duration without increasing adverse events. Given these lines of evidence, the investigators hypothesized that immediate EN following EUS-guided drainage of WON might shorten time to clinical success compared to the step-up approach. To examine this hypothesis, the investigators planned to conduct a multicenter randomized controlled trial comparing treatment duration between EN immediately after EUS-guided drainage versus the step-up approach in patients with symptomatic WON.
A surgery center includes a matrix of flow patterns and interaction nodes that are optimized by providing a physical structure that includes an admit/reception node, a pre-operative node, a surgical node, an acute recovery node and an observation node. The pre-operative node is located adjacent the admit/reception node. The surgical node is located adjacent the pre-operative node. The acute recovery node is located adjacent to the surgical node and between the surgical node and the observation node. The patient flow throughout each of the nodes is unidirectional. An instrument flow is circular and confined to the surgical node, a staff/physician flow includes a separate entry to the surgery center separate from the admit/reception node and the observation node, a supply flow is linear, and an environmental waste flow includes transitioning between a sterile zone and a non-sterile zone. The patient flow, the instrument flow, the staff/physician flow, the supply flow and the environmental waste flow intersect at the surgical node.
Nowadays, the prevalence of type 2 diabetes and its related metabolic diseases is rapidly rising in China. Obesity and early pathoglycemia will increase the risk of diabetes and related cardiovascular diseases severely. Therefore, more effective methods and strategies need to be found to reduce body weight, improve pathoglycemia, and control the development of this high-risk group to type 2 diabetes. As the most popular healthy dietary pattern in the world, the role of Mediterranean diet in the prevention of type 2 diabetes remains unclear. In addition, the protective role of Chinese traditional dietary pattern with lots of plant-based foods in the region of Jiangnan has not been clarified through intervention studies. Therefore, it is urgent to explore the feasibility and effectiveness of traditional Jiangnan diet and Mediterranean diet through dietary intervention studies in Chinese.

The effectiveness of healthy dietary patterns can be further enhanced by limiting dietary intake to achieve weight loss. Recently, the Spainish study found that energy-restricted Mediterranean diet + physical activity + behavioral interventions are more conducive to weight loss in overweight/obesity with prediabetes/type 2 diabetes compared with conventional Mediterranean dietary interventions. The 2019 Diabetes Management Standard of American Diabetes Association re-emphasizes the importance of moderate weight loss for delaying the progression of type 2 diabetes, and recommends that a reduction in dietary intake is 500-750 kcal/day to reach 1-2 pounds per week is suitable. At the same time, the American Clinical Endocrine Society and the American Endocrine Society have also updated the 2019 Comprehensive Management Guide for Type 2 Diabetes. The new guidelines point out that all overweight or obese patients with prediabetes or type 2 diabetes should pay attention to weight loss. And weight loss treatment should include specific lifestyle interventions, including calorie-restricted healthy dietary plan, physical activity and behavioral interventions.

Dietary intervention studies in the past mainly relied on dietary education. However, this study now provides a healthy and reasonable dietary model for the Chinese population through lifestyle intervention to clarify the improvement of cardiovascular metabolic risk such as overweight/obesity, glucose homeostasis, and the scientific basis for establishing a healthy dietary model which is suitable for Chinese population.
The invention relates to a quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation. The cellular target of yessotoxin (YTX) and analogues is the activation of phosphodiesterases (PDEs). The PDEs-YTX union emits a measurable signal. The union can be quantified by means of an affinity biosensor or fluorescence. The biosensor detects bimolecular interactions and makes it possible to determine the presence of YTX due to its interaction with PDEs. Plate fluorescence makes it possible to determine variations in the speed of degradation of fluorescent derivative anthranyloil-AMPc. The speed with which the PDEs degrade this molecule increases in the presence of YTX. The YTX inhibits the immunological activation of rat mastocytese and induces a cytotoxic effect in human hepatocarcinoma cells, which provides two therapeutic utilities of YTXs as anti-allergic and anti-tumoral compound.
Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. \> 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.
INTRODUCTION: The Medical Device Regulation (EU)745/2017, increased the regulatory requirements and thus the time and the cost associated with marketing medical devices. For a majority of medical device manufacturers, this has lead to reconsiderations of their product portfolio. The risk of important or essential devices being withdrawn is particularly relevant for pediatric patients and other rare disease patients where limited numbers of devices can be sold and hence the investment needed may not be recovered. This generates critical challenges and opportunities from a regulatory and public health perspective.
AREAS COVERED: This paper is based upon the experience of the authors who contributed to working groups, guidance development and research related to orphan and pediatric devices. We examine the use of medical devices in orphan and pediatric conditions, the relevant aspects of regulations and associated guidance, and we suggest possible policy and practice interventions to ensure the continued availability of essential devices for children and people with rare diseases.
EXPERT OPINION: We recommend a more proactive approach to identifying devices at risk and essential devices, increasing the use of exceptional market approvals, expanding the role of expert panels, engaging with the rare disease communities and supporting registries and standards.
The invention provides a drug liposome/p53 gene compound and a preparation method and application thereof. The compound is composed of a drug liposome containing resveratrol and a p53 gene. The invention further provides the preparation method of the drug liposome/p53 gene compound. The preparation method comprises the following steps: taking polypeptide type positive ion lipoid, auxiliary lipoid and the resveratrol as main raw materials, orderly adopting a film dispersion method, an ultrasonic hydration method and a gel chromatographic column separation method to prepare a drug liposome, and then mixing the drug liposome with the p53 gene to prepare the drug liposome/p53 gene compound through an electrostatic compounding method. The drug liposome/p53 gene compound provided by the invention activates the p38MAPK kinase activity through the resveratrol so as to induce the activation of the p53 gene, the p53 gene is enabled to express a wild type p53 protein, the antitumor effects of the resveratrol and the p53 gene are synergistically played to trigger the apoptosis of tumor cells, thereby achieving an aim of treating the tumor. The in vitro biological study shows that the compound has a certain cell proliferation inhibition ability, has high wild type p53 protein expression, provides a new thought for the tumor treatment and has a potential application value.
An interactive platform providing health care prevention is provided. The platform includes a plurality of doctor interfaces, each doctor interface being associated with a doctor or other health care provider participating in the platform, patient interfaces coupled to peripherals measuring and determining patient parameters associated with the patients' health, said patient interfaces receiving, patient information, instructions, data from peripherals, and so on. In one embodiment, each patient interface is associated with a particular patient. In another embodiment, an intermediate assistant is provided with a patient interface adapted to provide information to and receive information related to several patients. A master server in communication with the doctor and patient interfaces and adapted to collect information and present information through said interfaces. Rules and criteria are used by the master server to monitor the patients' parameters, send reminders to the patient interfaces, and multi-level alarms to the doctor interfaces and devices of third parties when the patient parameters do not meet criteria selected by the individual doctors for their patients.
Patients undergo CXR every 3 months for years 1-2, and every 6 months years 3-5. Patients with a suspicious or new nodule undergo a CT and may undergo a biopsy on study.